Shuai Shao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shuai Shao has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Fu Jie Shen
The Sixth Laboratory, National Vaccine and Serum Institute (NVSI), Beijing 101111, China
1 shared publicationHao Zhang
The Sixth Laboratory, National Vaccine and Serum Institute (NVSI), Beijing 101111, China
1 shared publication- Ji Guo Su
The Sixth Laboratory, National Vaccine and Serum Institute (NVSI), Beijing 101111, China
1 shared publication - Jing Zhang
The Sixth Laboratory, National Vaccine and Serum Institute (NVSI), Beijing 101111, China
1 shared publication Jun Wei Hou
The Sixth Laboratory, National Vaccine and Serum Institute (NVSI), Beijing 101111, China
1 shared publicationLi Fang Du
The Sixth Laboratory, National Vaccine and Serum Institute (NVSI), Beijing 101111, China
1 shared publication
Latest Publications
- 27 September 2024
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 385 (6716) , 1484-1491
Mutating a flexible region of the RSV F protein can stabilize the prefusion conformation
The respiratory syncytial virus (RSV) fusion (F) glycoprotein is highly immunogenic in its prefusion (pre-F) conformation. However, the protein is unstable, and its conformation must be stabilized for it to function effectively as an immunogen in vaccines. We present a mutagenesis strategy to arrest the RSV F protein in its pre-F state by blocking localized changes in protein structure that accompany large-scale conformational rearrangements. We generated a series of mutants and screened them in vitro to assess their potential for forming a stable pre-F. In animals, the immunogenicity of a representative mutant F protein, with a conformation confirmed by cryo–electron microscopy, elicited levels of neutralizing antibodies and protection against RSV-induced lung damage that were comparable to those of DS-Cav1, a pre-F used in a licensed vaccine.
- 27 September 2024
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 385 (6716) , 1484-1491
Mutating a flexible region of the RSV F protein can stabilize the prefusion conformation
The respiratory syncytial virus (RSV) fusion (F) glycoprotein is highly immunogenic in its prefusion (pre-F) conformation. However, the protein is unstable, and its conformation must be stabilized for it to function effectively as an immunogen in vaccines. We present a mutagenesis strategy to arrest the RSV F protein in its pre-F state by blocking localized changes in protein structure that accompany large-scale conformational rearrangements. We generated a series of mutants and screened them in vitro to assess their potential for forming a stable pre-F. In animals, the immunogenicity of a representative mutant F protein, with a conformation confirmed by cryo–electron microscopy, elicited levels of neutralizing antibodies and protection against RSV-induced lung damage that were comparable to those of DS-Cav1, a pre-F used in a licensed vaccine.